Novo Nordisk next-generation obesity drug beats Zepbound in new trial
The head-to-head result puts Novo's follow-up candidate against Eli Lilly's tirzepatide as the two companies compete on next-wave incretin data.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 27 18:21 ETSource: NewsNation
The wire
- 01NewsNation reports Novo Nordisk's next-generation weight-loss candidate outperformed Eli Lilly's Zepbound in a new trial.
- 02A direct comparison against tirzepatide is the benchmark prescribers and payers use when weighing newer incretin options.
- 03Dose levels, trial size, duration and safety details are not given in the report, and the data have not been reviewed by regulators.
From the source
Read at newsnationnow.comNovo’s next-gen weight-loss drug outperforms Zepbound in new trial
